IQV VS MRK Stock Comparison
Performance
IQV91/100
91/100
IQV returned -8.00% in the last 12 months. Based on SPY's performance of -13.62%, its performance is above average giving it a score of 91 of 100.
MRK100/100
100/100
MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
IQV69/100
69/100
17 analysts offer 12-month price targets for IQV. Together, they have an average target of 277.18, the most optimistic target put IQV at 320 within 12-months and the most pessimistic has IQV at 235.
MRK68/100
68/100
21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.
Technicals
IQV75/100
75/100
IQV receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.
MRK10/100
10/100
MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
IQV100/100
100/100
IQV has missed earnings 0 times in the last 20 quarters.
MRK53/100
53/100
MRK has missed earnings 3 times in the last 20 quarters.
Profit
IQV88/100
88/100
Out of the last 20 quarters, IQV has had 19 profitable quarters and has increased their profits year over year on 12 of them.
MRK66/100
66/100
Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.
Volatility
IQV49/100
49/100
IQV has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
MRK52/100
52/100
MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Dividend
IQV
"Dividend" not found for IQV
MRK100/100
100/100
MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
IQVIA Holdings Inc. Summary
New York Stock Exchange / IQV
Healthcare
Medical - Diagnostics & Research
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Merck & Co., Inc. Summary
New York Stock Exchange / MRK
Healthcare
Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare IQV to other companies in the same or a similar industry.